Evolent Health Gets a Buy Rating from Canaccord Genuity

In a report released yesterday, Richard Close from Canaccord Genuity assigned a Buy rating to Evolent Health (NYSE: EVH), with a price target of $24. The company’s shares closed on Friday at $19.50.

According to TipRanks.com, Close is a 5-star analyst with an average return of 11.9% and a 59.3% success rate. Close covers the Services sector, focusing on stocks such as Envision Healthcare, Hms Holdings Corp, and Premier Inc.

Currently, the analyst consensus on Evolent Health is Strong Buy and the average price target is $23.20, representing a 19.0% upside.

In a report issued on May 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.50 and a one-year low of $10.30. Currently, Evolent Health has an average volume of 827.1K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolent Health, Inc. engages in the provision of health system solutions. It includes consulting, population health technology and clinical and operational capabilities. The company was founded by Frank Williams, Seth Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.